Weaker technical forecast for BioCryst Pharmaceuticals as stock downgraded to Strong Sell Candidate. (Updated on July 30, 2021)
Sell candidate since 2021-07-30 PDF
The BioCryst Pharmaceuticals stock price fell by -3.82% on the last day (Friday, 30th Jul 2021) from $16.76 to $16.12. and has now fallen 3 days in a row. During the day the stock fluctuated 4.73% from a day low at $16.07 to a day high of $16.83. The price has been going up and down for this period, and there has been a 3.27% gain for the last 2 weeks. Volume has increased on the last day by 573 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $39.61 million.
The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 34.47% during the next 3 months and, with a 90% probability hold a price between $20.24 and $23.70 at the end of this 3-month period.
Signals & Forecast
Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The BioCryst Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $16.85 and $16.31. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, July 23, 2021, and so far it has fallen -6.60%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.
Support, Risk & Stop-loss
BioCryst Pharmaceuticals finds support from accumulated volume at $15.63 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.76 between high and low, or 4.73%. For the last week, the stock has had a daily average volatility of 3.76%.
Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.
Is BioCryst Pharmaceuticals stock A Buy?
The BioCryst Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe BioCryst Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Sell candidate.
Current score: -5.764
Predicted Opening Price for BioCryst Pharmaceuticals of Monday, August 2, 2021
The predicted opening price is based on yesterday's movements between high, low, and the closing price.
|Fair opening price August 2, 2021||Current price|
Remember To Visit Our YouTube Channel
Cowen is very positive about BCRX and gave it a "Outperform" rating on June 17, 2021. The price target was changed from $18.00 to $21.00.
Fibonacci Support & Resistance Levels
Accumulated Volume Support & Resistance Levels
Click to get the best stock tips daily for free!
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy SubscribersDon't miss out on the runners!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.